中广核同位素基地竣工试产 国产医用同位素供应实现新突破

Core Insights - The successful commissioning of the cyclotron at the medical isotope production base in Mianyang, Sichuan, marks a significant advancement in the autonomous production capacity of key medical isotopes such as Gallium-68, Copper-64, and Iodine-123 [1][2] Company Overview - China General Nuclear Power Corporation Isotope Company is a wholly-owned subsidiary of China General Nuclear Technology (000881), focusing on the research, production, sales, and service of nuclear medicines [2] - The company has developed a diversified product matrix of medical isotopes, addressing urgent clinical needs and cutting-edge research [2] Product Development - Gallium-68, produced through the company's self-developed Gallium generator, provides stable support for clinical applications despite its short half-life of 67.71 minutes [2] - Copper-64 offers new diagnostic methods for neuroendocrine tumors and Alzheimer's disease due to its superior imaging characteristics [2] - Zirconium-89 serves as a critical probe for antibody drug development, accelerating targeted therapy innovations [2] - Iodine-123 enhances diagnostic accuracy for thyroid and cardiac diseases with its low radiation and high imaging quality [2] Quality Management and Collaboration - The company adheres to Good Manufacturing Practice (GMP) standards, establishing a comprehensive quality management system covering facilities, processes, and quality control [3] - An open and shared research platform is available for universities, research institutions, and enterprises, promoting collaborative innovation in proton technology and new isotope development [3] Brand Development - The company launched its medical isotope brand "Hejia," symbolizing the commitment to improving human life through nuclear technology, alongside the registration of the "IsoNosis" trademark for its isotope products [3] Industry Impact - The autonomous development and stable supply of medical isotopes by the company significantly contribute to the collaborative growth of China's new medical isotope industry, enhancing the country's nuclear medicine sector [3] - The company aims to deepen cooperation with medical institutions and research units to improve diagnostic capabilities for major diseases and expedite the delivery of precision medical solutions to clinical settings [3]